Immune transcriptomes from hospitalized patients infected with the SARS-CoV-2 variants B.1.1.7 and B.1.1.7 carrying the E484K escape mutation

Fast-spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) energize the COVID-19 pandemic. B.1.1.7 (VOC-202012/01) has become the predominant variant in many countries and a new lineage (VOC-202102/02) harboring the E484K escape mutation in the B.1.1.7 background emerged in February 20211. This variant is of concern due to reduced neutralizing activity by vaccine-elicited antibodies2,3. However, it is not known whether this single amino acid change leads to an altered immune response. Here, we investigate differences in the immune transcriptome in hospitalized patients infected with either B.1.1.7 (n=28) or B.1.1.7+E484K (n=12). RNA-seq conducted on PBMCs isolated within five days after the onset of COVID symptoms demonstrated elevated activation of specific immune pathways, including JAK-STAT signaling, in B.1.1.7+E484K patients as compared to B.1.1.7. Longitudinal transcriptome studies demonstrated a delayed dampening of interferon-activated pathways in B.1.1.7+E484K patients. Prior vaccination with BNT162b vaccine (n=8 one dose; n=1 two doses) reduced the transcriptome inflammatory response to B.1.1.7+E484K infection relative to unvaccinated patients. Lastly, the immune transcriptome of patients infected with additional variants (B.1.258, B.1.1.163 and B.1.7.7) displayed a reduced activation compared to patients infected with B.1.1.7. Acquisition of the E484K substitution in the B.1.1.7 background elicits an altered immune response, which could impact disease progression.


Introduction
Over the past few months, several variants of concern (VOC) carrying specific mutations thought to enhance viral fitness have emerged. Specifically, B.1.351 4 and P.1 were of particular concern because they carry the mutation E484K within the receptor binding domain (RBD), which has been demonstrated to enhance escape from neutralizing antibody inhibition in vitro 2,3 and may be linked with reduced vaccination efficacy 5 . In We also investigated the impact of the BNT162b vaccine on both variants.
for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Data 1-4). The presence of SARS-CoV-2 was confirmed by PCR, followed by whole viral genome sequencing. PCA plots demonstrate a separation of the three cohorts, with group C shifting towards the non-COVID controls (Fig. 1b). Expression of a total of approximately 3,071 genes was significantly elevated within five days of reporting symptoms and these clustered in immune-relevant pathways (Fig. 1c). Expression of immune-related gene classes, including the highly activated JAK/STAT pathway, declined up to 95% after 15 days upon onset of COVID-19 ( Fig. 1c and Data 2,5,6). PCA plots showed separation between RNA-seq samples from non-COVID controls 6 and the two variants on first and second principal components (PC1 and PC2) (Fig. 2a). A higher number of differentially expressed genes (DEGs) were identified between patients infected with the for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted May 30, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Immune transcriptomes in patients infected with other SARS-CoV-2 variants
We also examined the immune transcriptome of patients infected with the variants  (Fig. 5d).

Discussion
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  The clinical course of SARS-CoV-2 infection has been well-characterized, ranging from asymptomatic to fatal disease 10 . Here we concentrated on the immune transcriptome response of cohorts of more severely ill hospitalized patients and followed response over three weeks from the time of symptom development. In these patients we found that the host transcriptome response to SARS-CoV-2 infection evolves rapidly with the most profound changes within five days of symptomology, dropping significantly over the next ten days, with further drop, but not normalization, within four weeks. In a previous study we documented that asymptomatic and minimally symptomatic SARS-CoV-2 infected individuals from the same general geographic area showed no significant differences to uninfected individuals by six weeks following infection 6 1.7 and B.1.1.7+E484K groups, respectively. Our study provided the opportunity to examine whether or not transcriptomes from those that survived were significantly different than those that expired from infection. No differences were found.
All individuals who died were over the age of 70 and had underlying medical conditions. Drug treatment including corticosteroid and antibody treatment could theoretically alter immune response. In this study the majority of this hospitalized population received corticosteroid treatment, which may have modified immune response, but as there were no significant differences in the percentage treated between B.1. 1.7 and B.1.1.7+E484K for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  A recent bulk RNA-seq immune transcriptome study also identified transcript categories, including interferon-activated genes, induced in COVID-19 patients but the variant was not defined 12 . As samples become available from patients with other variants, the degree of transcriptome variation will be able to be defined.
In summary, our study documents that the E484K mutation is sufficient to alter transcriptome response. This RBD escape mutation has evolved independently in several SARS-CoV-2 backgrounds, including B.1.1.7 9 with a single immunocompromised patient study demonstrating that it can occur within 10 days of infection 13 . Here, our significant for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.27.21257952 doi: medRxiv preprint differences in transcriptome response did not correlate with significant differences in clinical course but this could be due to the selection bias of only hospitalized patients being included in this study. The fact that variants can induce different host immune response has implications for the understanding of both innate and acquired immune response mechanisms. Further investigation of the reasons why these differences occur may help in design of vaccines and antibody treatments that may have more universal coverage of variant.

Limitations
The findings in this report are subject to several limitations. Our study focused on hospitalized patients in a specific geographic area. Our study focused on elderly patients with limited comparison to younger individuals. We have investigated the effect of the BNT162b vaccine but not of any other vaccine.

SARS-CoV-2 virus sequencing
RNA was extracted from patient's blood using a Maxwell RSC simply RNA Blood purification kit according to the manufacturer's instructions (Promega, USA). Library preparation and sequencing was performed as described 14 . In short, cDNA was obtained by using reverse transcriptase with random priming. Following cDNA synthesis, primers based on sequences from the ARTICnetwork were used to generate 400 bp amplicons in two different PCR pools. After merging of pools and amplification, libraries were constructed using QIASeq FX DNA Library UDI Kit following the manufacturer's instructions (Qiagen GmbH, North Rhine-Westphalia, Germany). This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Extraction of the buffy coat and purification of RNA
Whole blood was collected, and total RNA was extracted from the buffy coat and purified The raw data were subjected to QC analyses using the FastQC tool (version 0.11.9) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). mRNA-seq read quality control was done using Trimmomatic 15 (version 0.36) and STAR RNA-seq 16 (version STAR 2.5.4a) using 150 bp paired-end mode was used to align the reads (hg19).
HTSeq 17 (version 0.9.1) was to retrieve the raw counts and subsequently, R

Statistical analysis
For significance of each GSEA categoty, significantly regulated gene sets were evaluated with the Kolmogorov-Smirnov statistic. Demographic data were analyzed by Chi-square on GraphPad Prism software (version 9.0.0). All graphs were generated using GraphPad.
for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Data availability
The RNA-seq data of Non-COVID individual were obtained from GSE162562. The RNAseq data of COVID-19 patients infected by B.1.1.7 or B.1.1.7/E484K variant will be uploaded in GEO before publishing the manuscript.

Acknowledgments
Our gratitude goes to the patients who contributed to this study to advance our understanding of COVID-19. for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.      .1.1.7 or B.1.1.7+E484K  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Fig. 1a) and 10-15 (sample B in Fig. 1a)    This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.